<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Non-Hodgkin Lymphoma

Research    Non-Hodgkin Lymphoma

Louie Anderson’s Death Brings Attention to Diffuse Large B-cell Lymphoma

 Comedian Louie Anderson — known for his stand-up routines, as well as a hosting stint on “Family Feud,” his animated series “Life With Louie,” and a more recent role on the FX comedy series “Baskets” — died January 21of diffuse large B-cell lymphoma. He was 68.


Author Greg Glasgow | Publish Date January 25, 2022
Full Story

Research    Blood Cancer    Non-Hodgkin Lymphoma

Phase III clinical trial results support rituximab as new standard-of-care in pediatric Burkitt lymphoma

Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. The trial represents a major international collaboration between the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the Children’s Oncology Group (COG), and was led in the United States by Thomas Gross, MD, PhD, University of Colorado Cancer Center investigator and pediatric oncologist at Children’s Hospital Colorado, and in Europe by Véronique Minard-Colin, MD and Catherine Patte, MD, both pediatric oncologists at the Gustave Roussy Department of Child and Adolescent Oncology in Paris, France. The addition of rituximab decreased treatment failures by 70 percent resulting in a 10 percent increase in the three-year survival rate seen with chemotherapy alone (LMB protocol).


Author Cancer Center | Publish Date June 03, 2020
Full Story

CU Cancer Center In the News

Cancer Health

2024 Cancer Health 25: People Who Power Clinical Trials

news outletCancer Health
Publish DateJune 11, 2024

This year's Cancer Health 25 highlights the transformative power and promise of clinical trials. University of Colorado Cancer Center member Jessica McDermott, MD, MSCS, is leading clinical trials at both the CU Cancer Center and the Rocky Mountain Regional Veterans Affairs Medical Center. Additionally, she serves as the CU Cancer Center's deputy associate director for diversity and inclusion in clinical research.

Full Story
Cancer Network

Learning to “Aim High” Within Male-Dominated Fields in Public Health

news outletCancer Network
Publish DateJune 10, 2024

Cathy Bradley, PhD, deputy director of the Colorado University Cancer Center and dean of the Colorado School of Public Health, is a trailblazer in health economics. At a Breaking Barriers: Women in Oncology discussion, she shared insights on overcoming challenges as a woman in a male-dominated field and discussed her research on the impact of employment on cancer patients' health insurance decisions.

Full Story
Cancer Therapy Advisor

Telisotuzumab Vedotin Yields Durable Responses in c-Met-Expressing NSCLC

news outletCancer Therapy Advisor
Publish DateJune 07, 2024

Telisotuzumab vedotin shows promising activity in previously treated, c-Met-overexpressing, EGFR-wild-type nonsquamous non-small cell lung cancer (NSCLC), as presented by CU Cancer Center member David Ross Camidge, MD, PhD, at the ASCO Annual Meeting 2024. This phase 2 LUMINOSITY trial (NCT03539536) involved 161 patients with advanced or metastatic NSCLC and the overall response rate was 28.6%, with median progression-free survival of 5.7 months and median overall survival of 14.5 months.

Full Story
Association of Cancer Care Centers

The Centralized Tracking and Management of Incidental Lung Nodule Findings

news outletAssociation of Cancer Care Centers
Publish DateJune 07, 2024

The University of Colorado Cancer Center has been honored with the 2024 ACCC Innovator Award for creating a community-wide safety net for the centralized tracking and management of incidental lung nodule findings. This innovative approach led to a 2,514% increase in actively managed patients. To handle this surge, the center employs enterprise intelligence software to automatically analyze imaging results and identify high-risk patients, reducing patient wait times from 34 days to 5 days. ACCCBuzz interviewed Nina Thomas, MD, director of the Thoracic Malignancy Pillar, to discuss this achievement.

Full Story